Dr Li on the Rationale of the MoonRISe-1 Trial in NMIBC
Nadofaragene Firadenovec Demonstrates Durable 5-Year Activity in NMIBC
UGN-102 With/Without TURBT Produces Similar DOR and DFS in Newly Diagnosed and Recurrent NMIBC
Dr Wang on the Role of Active Surveillance in Patients With Renal Masses